News
Company News: Curetis Group: Ares Genetics Receives Funding Commitment for EUR 1.6 Mio. Project; Curetis Announces Non-Audited Financial Results for 2017
— Curetis subsidiary Ares Genetics receives funding commitment from Austrian Research Promotion Agency (FFG) for EUR 1.6 million project „The Digital Microbe“
— „The Digital Microbe“ project builds on GEAR platform to develop machine learning tools to combat antibiotic resistances
— Curetis Group announces preliminary, non-audited financial results for 2017
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis”), a developer of next-level molecular diagnostic solutions, today announced that Ares Genetics GmbH (Vienna, Austria), a wholly-owned subsidiary of Curetis, has received notice from the Austrian Research Promotion Agency (FFG) that it has been awarded a grant for a EUR 1.6 million research project.
Company News: Life Science Inkubator (LSI) Bonn for the first time supports pharma industry spin-out
— Merck spin-off Silvacx receives seed financing of almost EUR 2 million
Life Science Inkubator GmbH (LSI) for the first time supports a research project originating from a pharma company. The project called Silvacx is a spin-off from Merck AG and is developing novel delivery technologies for cancer immunotherapy.
Company News: Curetis and MGI Advance Strategic Partnership in NGS-Based Molecular Microbiology
— Inked new collaboration and commercialization deals with MGI to leverage Curetis´ sample preparation technology
— Enabling short-term commercialization of NGS-based molecular microbiology
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that the Company is advancing its strategic alliance in NGS-based infectious disease testing. To this end, Curetis has signed a Supply and Authorization Agreement as well as a further R&D Collaboration and Service Agreement with MGI, a fully-owned subsidiary of BGI Group, one of the world’s leading genome sequencing centers headquartered in Shenzhen, Guangdong, P. R. China.
Company News: Curetis Expects Near-Term FDA Decision on De Novo Request
– Review of the Unyvero System and Lower Respiratory Tract (LRT) Cartridge is nearing completion
– U.S. commercial team and operational infrastructure in place
Curetis N.V. (the “Company” and, together with Curetis USA Inc. and Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today provided a status update on the FDA De Novo filing for the Company’s Unyvero System and LRT Cartridge for the diagnosis of lower respiratory tract infections.